Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Brooklyn ImmunoTherapeutics stock opened at $0.21 on Thursday. The stock has a market cap of $12.07 million, a P/E ratio of -0.56 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10. The firm’s fifty day moving average price is $1.71 and its 200-day moving average price is $1.96.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.